Warther Private Wealth’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.7M Sell
411,074
-108,406
-21% -$4.66M 4.32% 10
2026
Q1
$19.1M Buy
519,480
+100,652
+24% +$4.77M 4.48% 7
2025
Q4
$21.3M Buy
418,828
+10,833
+3% +$554K 5.09% 5
2025
Q3
$22.6M Buy
407,995
+30,263
+8% +$1.77M 5.36% 5
2025
Q2
$26.1M Buy
377,732
+123,392
+49% +$8.39M 6.78% 6
2025
Q1
$17.7M Buy
254,340
+242,319
+2,016% +$20M 5.81% 9
2024
Q4
$1.03M Buy
12,021
+1,497
+14% +$162K 0.35% 30
2024
Q3
$1.25M Sell
10,524
-4
-0% -$533 0.44% 29
2024
Q2
$1.5M Buy
10,528
+8,372
+388% +$1.11M 0.59% 26
2024
Q1
$277K Buy
+2,156
New +$257K 0.12% 48

Other funds holding NVO

Warther Private Wealth's NVO Position: Q2 2026 in Review

Warther Private Wealth reduced its Novo Nordisk (NVO) stake by 21% in Q2 2026, selling an estimated $4.66M and leaving 411,074 shares worth $19.7M. The position accounts for 4.32% of the portfolio, ranked #10.

Warther Private Wealth first reported a position in NVO in Q1 2024 and has held it in 10 quarters since. The position peaked at $26.1M in Q2 2025. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Warther Private Wealth held 411,074 shares of Novo Nordisk worth $19.7M as of Q2 2026.
  • Warther Private Wealth sold 108,406 Novo Nordisk shares in Q2 2026, an estimated $4.66M.
  • Novo Nordisk made up 4.32% of Warther Private Wealth's portfolio in Q2 2026, its #10 holding.
  • Warther Private Wealth first reported a position in Novo Nordisk in Q1 2024 and has held it in 10 quarters since.
  • Warther Private Wealth's Novo Nordisk position peaked at $26.1M in Q2 2025.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Warther Private Wealth's 13F filing for Q2 2026, filed 14 Aug 2026.